

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

ELECTION OF MEANS OF RECEIPT OF CORPORATE COMMUNICATIONS

The Company announces that, in accordance with the GEM Listing Rules and the articles of association of the Company, it is making arrangements to ascertain the preference of the Shareholders in respect of means of receipt of the Corporate Communications.

If the Company does not receive the duly completed and signed Reply Form or any response in writing indicating any objection from a Shareholder by 26 January 2024, such Shareholder is deemed to have consented to receive the Website Version of all future Corporate Communications.

INTRODUCTION

The Company announces that, in accordance with the GEM Listing Rules and the articles of association of the Company, it is making arrangements to ascertain the preference of the Shareholders in respect of means of receipt of the Corporate Communications.

PROPOSED ARRANGEMENTS

In accordance with the GEM Listing Rules, the Company is making available the following options for the Shareholders to elect means of receipt of future Corporate Communications:

1. The Company will send the first-time notification dated 29 December 2023 together with the Reply Form to the Shareholders to enable them to elect any of the following options:

Option 1: to access all future Corporate Communications by electronic means through the Stock Exchange's website at www.hkexnews.hk and the Company's website at www.sinopharmtech.com.hk (the "**Website Version**") instead of receiving printed copies, provided that for all Actionable Corporate Communications and the notifications thereof, the same will be sent to the Shareholders individually by email; or

Option 2: to receive both the printed English and Chinese versions of all future Corporate Communications for one year.

2. To support environmental protection and enhance efficient communication with the Shareholders, the Company encourages and recommends the Shareholders to select Option 1 to receive the Website Version of all future Corporate Communications. To make an election, the Shareholders shall complete the Reply Form in accordance with the instructions printed thereon and sign and return the same by mail or by hand to the Company at Unit 1802, 18/F, Ruttonjee House, Ruttonjee Centre, 11 Duddell Street, Central, Hong Kong. Please use own envelope stuck with stamp to return the Reply Form to the Company. Shareholders may also send email with a scanned copy of the duly completed and signed Reply Form to groupadmin@sinopharmtech.com.hk.
3. If a Shareholder elects to receive the Website Version of future Corporate Communications, he / she is requested to provide an email address in the Reply Form for the purpose of receiving all future Actionable Corporate Communications and the notifications thereof in electronic form from the Company. It is the responsibility of the Shareholders to provide an email address that is valid and functional. If no valid and functional email address is provided by a Shareholder, the Company will send to such Shareholder by post all future Actionable Corporate Communications and the notifications thereof in printed form, until such time when such Shareholder has provided a valid and functional email address to the Company for receiving the same.
4. If the Company does not receive the duly completed and signed Reply Form or any response in writing indicating any objection from a Shareholder by 26 January 2024, and until the Shareholder informs the Company by reasonable prior notice in writing to the Company at Unit 1802, 18/F, Ruttonjee House, Ruttonjee Centre, 11 Duddell Street, Central, Hong Kong or by email to groupadmin@sinopharmtech.com.hk, such Shareholder is deemed to have consented to receive the Website Version of all future Corporate Communications.
5. If a Shareholder has elected in the Reply Form to receive printed version of the Corporate Communications, the Company will send printed copies of the Corporate Communications to the Shareholders together with a letter and a change request form for the purposes of receiving the Website Version of all future Corporate Communications.

6. Shareholders are also entitled at any time by reasonable prior notice in writing to the Company at Unit 1802, 18/F, Ruttonjee House, Ruttonjee Centre, 11 Duddell Street, Central, Hong Kong or by email to groupadmin@sinopharmtech.com.hk to change their choice of means of receipt of future Corporate Communications. Even if a Shareholder has chosen (or are deemed to have consented) to receive the Website Version of future Corporate Communications but for any reason has difficulty in receiving or gaining access to the Website Version of the Corporate Communications, the Company will, upon request in writing by the Shareholder or by email to groupadmin@sinopharmtech.com.hk, send the printed form of the Corporate Communications to the Shareholder free of charge.

DEFINITIONS

“Actionable Corporate Communications”	any Corporate Communication from the Company that seeks instructions from its securities holders on how they wish to exercise their rights or make an election as the securities holders of the Company
“Company”	Sinopharm Tech Holdings Limited, a company incorporated in the Cayman Islands with limited liability, the shares of which are listed on GEM of the Stock Exchange
“Corporate Communication”	document(s) issued or to be issued by the Company for the information or action of holders of any of the Company’s securities, including but not limited to: (a) the directors’ reports, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) notice of meeting; (d) listing document; (e) circular; and (f) proxy form
“GEM Listing Rules”	Rules Governing the Listing of Securities on GEM of the Stock Exchange
“Reply Form”	a reply form for the election of means of receipt of Corporate Communications
“Shareholder(s)”	holder(s) of the Share(s)
“Share(s)”	ordinary share(s) of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Website Version”	the version of the Corporate Communications in electronic form published, in both English and Chinese, on the Stock Exchange’s and the Company’s website

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
HO Kam Kin
Executive Director

Hong Kong, 29 December 2023

As at the date of this announcement, the Board comprises Mr. HO Kam Kin and Ms. KWOK Shuk Yi as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence, Mr. HSU Dong An and Mr. HEUNG Pik Lun as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for a minimum period of 7 days from the date of its publication and on the website of the Company at <http://www.sinopharmtech.com.hk>